TLTFF (Theralase Technologies) Change In Receivables : $-0.01 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies Change In Receivables?

Theralase Technologies's change in receivables for the quarter that ended in Dec. 2024 was $-0.03 Mil. It means Theralase Technologies's Accounts Receivable increased by $0.03 Mil from Sep. 2024 to Dec. 2024 .

Theralase Technologies's change in receivables for the fiscal year that ended in Dec. 2024 was $-0.01 Mil. It means Theralase Technologies's Accounts Receivable increased by $0.01 Mil from Dec. 2023 to Dec. 2024 .

Theralase Technologies's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.12 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Theralase Technologies's Days Sales Outstanding for the three months ended in Dec. 2024 was 37.07.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Theralase Technologies's liquidation value for the three months ended in Dec. 2024 was $-0.36 Mil.

Theralase Technologies Change In Receivables Historical Data

The historical data trend for Theralase Technologies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Change In Receivables Chart

Theralase Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

0.30

0.18

-0.02

-0.01

Theralase Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-0.09	0.04	-	-0.02	-0.03

Theralase Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

Theralase Technologies (OTCPK:TLTFF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Theralase Technologies's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.117	/	0.288	*	91
=	37.07

2. In Ben Graham's calculation of liquidation value, Theralase Technologies's accounts receivable are only considered to be worth 75% of book value:

Theralase Technologies's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.189	-	0.828	+	0.75 * 0.117	+	0.5 * 0.383
=	-0.36

Theralase Technologies Change In Receivables Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

TTX:Germany TTX:Germany TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.